Dr. Markus Kostrzewa joined Bruker in 1998 as Head of the new R&D group “Bioanalytical Development“, establishing molecular biology and biology related development at Bruker Daltonik GmbH. The initial focus went to development of DNA analysis methods by MALDI-TOF mass spectrometry, and “Clinical Proteomics”, the latter covering methods, consumables and software for mass spectrometry profiling of body fluids and tissues. His R&D group progressed to successful development of microorganism identification by Bruker’s MALDI-TOF mass spectrometry, today globally known as the “MALDI Biotyper” system. Dr. Kostrzewa became Director Molecular Biology R&D in 2005, then promoted to Vice President Clinical Mass Spectrometry R&D in 2012, which was broadened to Vice President Microbiology & Diagnostics R&D in 2017. Since 2019, Dr. Kostrzewa is Bruker’s Senior Vice President Microbiology & Diagnostics R&D, Regulatory and Scientific Affairs, heading innovation at Bruker Microbiology and Diagnostics. This includes strategic planning of innovative products and driving regulatory approval processes (IVD-CE labelling, FDA clearance, ISO/AOAC certification for Food market).